Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$36.96
-1.04 (-2.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-32.3M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-63.5%
↓Gross Margin
25.4%
↓Debt/Equity
1.21
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.4%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $471.3M · net income $-333.5M · FCF $-32.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $471.3M | $471.3M | $561.6M | $673.0M | $491.5M |
| Net Income | $-333.5M | $-333.5M | $-89.6M | $-26.2M | $-63.1M |
| EBITDA | $-243.1M | $-243.1M | $-26.9M | $3.2M | $-44.2M |
| EPS | -3.34 | -3.34 | -0.90 | -0.26 | -0.63 |
| Gross Margin | 25.4% | 25.4% | 30.8% | 28.1% | 40.5% |
| Operating Margin | -18.0% | -18.0% | -6.5% | 1.4% | 2.3% |
| Net Margin | -70.8% | -70.8% | -16.0% | -3.9% | -12.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.21 | 1.21 | 0.73 | 0.69 | 0.55 |
| Current Ratio | 0.63 | 0.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32.3M | $-32.3M | $-9.4M | $-144.5M | $-87.7M |
| Returns | |||||
| ROE | -63.5% | -63.5% | -10.5% | -2.8% | -6.5% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 747.39 | — |
| P/B | 7.03 | 7.03 | 1.58 | 2.02 | 1.87 |
| Growth & Yield | |||||
| Revenue Growth | -16.1% | -16.1% | -16.5% | 36.9% | — |
| EPS Growth | -271.1% | -271.1% | -246.2% | 58.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+83.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.90 → -3.34
Residual
+83.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.